Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)
Clinical trial NCT00778830 · COMPLETED
Trial details
- NCT number
- NCT00778830
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-02-01
- Primary completion
- 2014-04-01
- Enrollment
- 289
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.